GROW (Glioma Specialists Reaching Out With Support) Support
NCT ID: NCT05233215
Last Updated: 2023-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2022-07-31
2024-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Coping With High Grade Glioma
NCT00815152
Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner
NCT02129335
Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
NCT02375841
Mind-Body Intervention in Glioma Couples
NCT03244995
Long Term Survivors of High-grade Glioma and Their Caregivers
NCT02965144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The research study procedures include: screening for eligibility and study interventions including filling out questionnaires and virtual or in-clinic supportive follow up visits to identify additional supportive needs that may arise.
Participants will be in this research study for up to 6 months.
It is expected that about 40 people will take part in this research study.
The Levitan-Zabin Fund for GROW Support is supporting this research study by providing funds for research team members to do this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GROW Support Program
Patient participants will fill out questionnaires about emotional and physical health with responses used to develop an individualized survivorship plan conducted through 1x monthly virtual or in-clinic check-ins as well as GROW support meetings as needed for 6 months.
Caregiver participants will fill out questionnaires used to develop patient individualized survivorship plan and participate in 1x monthly check-in meetings with patients or separately for 6 months.
GROW (Glioma Specialists Reaching Out With Support) Support Program
Follow-up survivorship care plan for patients and caregivers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GROW (Glioma Specialists Reaching Out With Support) Support Program
Follow-up survivorship care plan for patients and caregivers
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with low grade glioma (WHO grade 1 or 2)
* Completed active treatment within the last 2 years and are undergoing surveillance follow-up
* Must have at least one caregiver willing to participate as indicated below
* Read and comprehend English such that they are able to complete required intervention sessions and psychosocial battery in English and are able to understand and willing to sign an electronic informed consent document.
* Confirms willingness to undergo initial and follow-up questionnaire battery.
* Must be at least 18 years of age
* Read and comprehend English such that they are able to complete required intervention sessions and psychosocial battery in English and able to understand and willing to sign an electronic informed consent document
* Consider themselves personally involved in the patient's care and decisions about the care they receive.
Exclusion Criteria
* Psychotic disorders and
* Confusion or altered mental state that would prohibit understanding and giving of informed consent. However, if the patient's bipolar disorder or psychotic disorder is currently treated/managed, the patient will be eligible for the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dana-Farber Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Timothy S Sannes, PhD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-650
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.